Tag Archive for: acquisition

Servier acquires potential treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder

/in

Suresnes (France), September 8, 2025 – Servier, an independent international pharmaceutical group governed by a foundation, today announced that it has entered into a definitive agreement with Kaerus Bioscience for the acquisition of KER-0193, a potential treatment for Fragile X syndrome (FXS), the most common genetic cause of autism spectrum disorder (ASD). This acquisition demonstrates Servier’s […]

Read more

KKR Announces Strategic Acquisition of HealthCare Royalty Partners, Expanding the Firm’s Health Care Franchise and Enhancing its Life Sciences Strategy

/in

New York, July 30, 2025 – KKR & Co. Inc., a leading global investment firm, today announced that it has acquired a majority ownership stake in HealthCare Royalty Partners (HCRx), a leading biopharma royalty acquisition company. This strategic partnership will enable KKR to enhance its capabilities in biopharma royalty and credit investing, while expanding the […]

Read more

Sanofi to acquire next-generation vaccine biotech Vicebio for US$1.6 billion

/in

Sanofi will gain access to Molecular Clamp technology that enables development of next-generation multivalent vaccines against respiratory pathogens and beyond Lead asset VXB-241 is a bivalent vaccine targeting Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV), currently in exploratory Phase 1 Upfront payment of US$1.15 billion and milestones up to US$450 million London, UK, 22 […]

Read more

Weekly round-up: How do you turn a 10-person biotech into a $1.1 billion company sale in the space of seven years?

/in

During the BIO-Europe conference in Stockholm, Optimum co-hosted a special reception featuring a fireside chat with Renée Aguiar-Lucander, former CEO of Calliditas, who led the Swedish company since 2017 until recently – taking it from small biotech to its $1.1 billion acquisition. Here, we tell the story of her remarkable seven-year journey with the firm.  Novo […]

Read more

Optimum’s hot topic: How do you turn a 10-person biotech into a $1.1 billion company sale in the space of seven years?

/in

During the BIO-Europe conference in Stockholm, Optimum co-hosted a special reception featuring a fireside chat with Renée Aguiar-Lucander, former CEO of Calliditas, who led the Swedish company since 2017 until recently – taking it from small biotech to its $1.1 billion acquisition. Here, we tell the story of her remarkable seven-year journey with the firm.  […]

Read more